Approved products include Naglazyme for mucopolysaccharidosis VI.

Approved products include Naglazyme for mucopolysaccharidosis VI , a product wholly by BioMarin by BioMarin; Aldurazyme for mucopolysaccharidosis I , a product which BioMarin developed through a 50 / 50 joint venture with Genzyme Corporation and Kuvan Tablets, a product for the treatment of phenylketonuria , in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, develops. Other product candidates are 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG – PAL , the. Currently in Phase 1 clinical development for the treatment of PKU For more information, please visit Information on BioMarin’s website is not incorporated by reference into this press release..

BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 to 50 % of the estimated 50,000 identified PKU patients in the developed world.. ###Title: tonsillectomy for obstructive sleep apnea in obese children Moderators: Dary J. MD, Ron B. Mitchell, MDAbout the AAO – HNS and Head-The American Academy of Otolaryngology Neck Surgery (one of the oldest medical associations in the nation, represents more than 12,000 physicians and allied health professionals the the diagnosis and treatment of diseases of the ears, throat , and related structures of the head and neck. The Academy serves its members by development of the development of the science and art of medicine related to otolaryngology and by representing the specialty in governmental and socioeconomic aspects of the organization vision.Besides the 960 – site printing report, The sanitary from smoking, released the U.S. Department of Health and Human , a new interactive science database containing more than 1,600 major products quoted contained in the report available, over the Internet (). The database can be can be used to provide detailed information about the specific health effects of smoking as well custom analyzes illnesses and ailments tables and graphs are. Note: All HHS press releases.

Dr. Carmona said it was never too late to stop smoking. Smoking at 65 and older reduce by nearly 50 % a person’s risk dying an smoking-related disease.